Home / Health / COVID Antivirals Lose Punch: New Research Questions Efficacy
COVID Antivirals Lose Punch: New Research Questions Efficacy
24 Aug
Summary
- New research indicates COVID antivirals are less effective due to high vaccination rates.
- Paxlovid may still offer some benefit, but Lagevrio's role is questionable.
- Antivirals were costly, with Australia spending over A$2 billion on them.
New research indicates that COVID antivirals, previously vital for reducing severe illness, hospitalization, and death, are no longer as effective. High vaccination rates and previous infections have built significant immunity in the population, lessening the impact of these drugs.
While early trials showed substantial benefits for Paxlovid and Lagevrio, more recent studies in vaccinated individuals found no reduction in severe outcomes. The cost of these treatments was considerable, with Australia spending over A$2 billion on Paxlovid and Lagevrio between mid-2022 and mid-2025.
Although observational studies suggest Paxlovid might still reduce hospitalizations and deaths, its benefits are becoming marginal. The role of Lagevrio is particularly uncertain, with mixed results on its effectiveness. Potential harms include side effects and drug interactions, especially for Paxlovid.
Australia's Pharmaceutical Benefits Advisory Committee is scheduled to review COVID antivirals later in 2026, considering their costs and benefits. This reassessment is supported by findings that suggest a diminished return on investment for these medications.
